Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic

Xianghui Li^1,2, Yabo Zhang^1,2, Libing He^1,2, Jiangzhe Si^1,2, Shuai Qiu^1,2, Yuhua He^1,2, Jiacun Wei^1,2, Zhili Wang^1,2, Longxiang Xie^1,2✉, Yanzhang Li^1,2✉, Tieshan Teng^1,2✉

1. Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
2. Henan International Joint Laboratory of Nuclear Protein Regulation, School of Basic Medical Science, Henan University, Kaifeng, Henan 475004, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Citation:
Li X, Zhang Y, He L, Si J, Qiu S, He Y, Wei J, Wang Z, Xie L, Li Y, Teng T. Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic. Int J Biol Sci 2022; 18(5):1865-1877. doi:10.7150/ijbs.66369. Available from https://www.ijbs.com/v18p1865.htm

Abstract

Following onset of the first recorded case of Coronavirus disease 2019 (COVID-19) in December 2019, more than 269 million cases and over 5.3 million deaths have been confirmed worldwide. COVID-19 is a highly infectious pneumonia, caused by a novel virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, it poses a severe threat to human health across the globe, a trend that is likely to persist in the foreseeable future. This paper reviews SARS-CoV-2 immunity, the latest development of anti-SARS-CoV-2 drugs as well as exploring in detail, immune escape induced by SARS-CoV-2. We expect that the findings will provide a basis for COVID-19 prevention and treatment.

Keywords: COVID-19, SARS-CoV-2, immunity, potential drugs